Blogs & News

An Overview of Prostate Cancer Detection Standard of Care and The Role of MRI for Early Detection of Prostate Cancer

Randall W. Jones, D.Eng. (PhD, MBA) EARLY DETECTION through Screening Population-Based Screening Studies Screening for Prostate Cancer (PCa) continues to

The Use Of Prostatid In Cancer Detection, Diagnosis And Screening

Overview: ProstatIDTM is North America’s first FDA-Cleared Prostate Cancer SCREENING, Detection and Diagnostic AI software. With 94% AUROC (Area under

ConcertAI’s TeraRecon and Bot Image, Inc. Partnership 

 TeraRecon, on March 18, 2023 CAMBRIDGE, Mass., Mar. 18,2023  /PRNewswire/ — The Eureka Clinical AI platform, from ConcertAI’s TeraRecon, now

Omaha-Based MRI Medical Device Company, Bot Image, Receives FDA Clearance for AI

FOR IMMEDIATE RELEASE Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD software to…

Just released by Dr. Randall W Jones

Just released, The Healthcare Disruptor, by Dr. Randall W Jones. Dr. Jones writes about his journey from rural cowboy to medical device expert and CEO challenging the healthcare system with his inventions…

Bot Image Makes the List: 10 Most Advanced Medical Imaging Solution Providers 2022

Bot Image Inc: Facilitating Early Detection through Disruptive Technology In undetermined and unsettled times, one must be open to…

A Trailblazing Entrepreneur, Bringing Highly Accurate MRI Interpretation Software to Physicians

DR. RANDALL W. JONES FOUNDER & CEO OF BOT IMAGE, INC From joining the military at a young age to excelling at civilian jobs to…

Prostate Cancer Treatment can be safely delayed and inexpensively and accurately monitored thanks to AI

Bot Image, Inc., a Nebraska and Maine based Artificial Intelligence medical device company, has received FDA-clearance on its ProstatIDTM AI

ProstatID kick-starts your Prostate MRI program

ProstatID, THE AI software FDA-cleared for not only detection and diagnosis of PCa, but also for screening using bpMRI.   Yes,

New Studies Demonstrate that Bot Image’s Prostate Cancer AI Software Outperforms the Field

Bot Image, Inc., a Nebraska and Maine based Artificial Intelligence medical device company (, raised the performance bar with its

Bot Image highlights performance of ProstatID in study

AI medical device company Bot Image is highlighting the performance of its ProstatID in a study evaluating its ability to detect, diagnose, and screen for prostate cancer.

Dr. Randall Jones participates in GE’s Innovation Theater at RSNA Dec 2022

Dr. Randall Jones, CEO of BotImage and two other AI companies chosen to participate with GE HealthCare presenting during GE’s Innovation

RSNA 2022 – Accelerating digitally enabled care…

Dr. Randall Jones is one of the speakers this year. Come visit the GE Healthcare Booth #7324 on Nov. 30th at 1:35pm CT.

Saving Lives, Improving Prostate Cancer Detection with Artificial Intelligence

A prostate cancer diagnosis can be devastating news for the one in seven men who develop the disease in their lifetimes. Annually, 30,000…

10 Questions With Our Founder

We recently sat down with our founder to ask 10 questions about the company, the industry, and what are the options men have when facing…

A Conversation With Our CEO Dr. Randall Jones, PhD, MBA

We recently sat down with our CEO in his library to discuss the mission, vision, and values of Bot Image. We discussed ProstatID and the…

Successful Beta Test

We’re proud to announce that in partnership with our beta testing site, we processed our first test case using the cloud-based architecture on 6/18/2020.

ProstatID Passes FDA 510(k) Administrative Review

The Bot Image team has been hard at work trying to obtain FDA clearance. We’re excited to announce that we have passed the first major milestone on July 21, 2020.

Bot Image On Trial Site News

Trial Site News features the latest coverage of clinical research. Read the article here: